Die rhetorische Designanalyse und Buchanans ›Design-Argument‹ – am Beispiel des Lego Star Wars AT-AT Walker 4483.

With his concept of the »design argument«, Richard Buchanan presented a classification system in 1985 that allows us to differentiate different impact goals in analysing design artefacts. In the present article, this system is combined with the method of rhetorical design analysis after the Bernese model. Using a Lego set as an example, it is demonstrated how designers apply rhetorical techniques to achieve affects and how these function. Furthermore, it is explained how the emotions of adult Lego fans are prompted and influenced by building the (and playing with the) Lego Star Wars AT-AT Walker #4483 model. At the same time, this case study makes a contribution to the cultural history of the pop-culture cross-over of Lego and Star Wars

Tagungsbericht zur dritten Tagung der DGTF zum Thema «Forschung Recherche Research».

Die dritte Tagung der DGTF hatte das Thema "Forschung Recherche Research" und fand am 28. und 29. Januar 2005 im Mannheimer Kunstverein statt. Drei "Impulsreferate" und vier Projektpräsentationen zum Thema wurden von Panels flankiert, in denen die vorgestellten Positionen der Designtheorie und -forschung von eingeladenen Gästen und den Zuschauern diskutiert wurden. Im Zentrum der Diskussionen standen dabei die Fragen nach dem Begriff der Designtheorie selbst und nach spezifischen Methoden der Designforschung und ihrer Realisierung in Forschungsprojekten. Alle Beiträge wie auch die Diskussionen liegen als Tondokumente unter www.dgtf.de/97.0.html vor

Effects of lumacaftor—ivacaftor therapy on cystic fibrosis transmembrane conductance regulator function in F508del homozygous patients with cystic fibrosis aged 2–11 years

Rationale: Lumacaftor/ivacaftor was approved for the treatment of patients with cystic fibrosis who are homozygous for F508del aged 2 years and older following positive results from phase three trials. However, the improvement in CFTR function associated with lumacaftor/ivacaftor has only been studied in patients over 12 years of age, while the rescue potential in younger children is unknown.Methods: In a prospective study, we aimed to evaluate the effect of lumacaftor/ivacaftor on the CFTR biomarkers sweat chloride concentration and intestinal current measurement as well as clinical outcome parameters in F508del homozygous CF patients 2–11 years before and 8–16 weeks after treatment initiation.Results: A total of 13 children with CF homozygous for F508del aged 2–11 years were enrolled and 12 patients were analyzed. Lumacaftor/ivacaftor treatment reduced sweat chloride concentration by 26.8 mmol/L (p = 0.0006) and showed a mean improvement in CFTR activity, as assessed by intestinal current measurement in the rectal epithelium, of 30.5% compared to normal (p = 0.0015), exceeding previous findings of 17.7% of normal in CF patients homozygous for F508del aged 12 years and older.Conclusion: Lumacaftor/ivacaftor partially restores F508del CFTR function in children with CF who are homozygous for F508del, aged 2–11 years, to a level of CFTR activity seen in patients with CFTR variants with residual function. These results are consistent with the partial short-term improvement in clinical parameters